1-6 of 6
Houston Holmes, MD
Close
Sort by
Journal Articles

KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study

Michael L. Wang, MD, Javier Munoz, MD, Andre Goy, MD, Frederick L. Locke, MD, Caron A. Jacobson, MD MMSc, Brian T. Hill, MD, John M. Timmerman, MD, Houston Holmes, MD, Samantha Jaglowski, MDMPH, Ian W. Flinn, MD PhD, Peter A. McSweeney, MD, David B. Miklos, MD PhD, John M. Pagel, MD PhD DSc, Marie Jose Kersten, MD PhD, Weimin Peng, MS, Lianqing Zheng, PhD, John M. Rossi, MS, Rajul K. Jain, MD, Arati V. Rao, MD, Patrick M Reagan, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 754.
https://doi.org/10.1182/blood-2019-126064
Published: 2019
Journal Articles

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

William G. Wierda, MD PhD, Michael R. Bishop, MD, Olalekan O. Oluwole, MBBS, MPH, Aaron C. Logan, MD PhD, Maria R. Baer, MD, William B. Donnellan, MD, Kristen M. O'Dwyer, MD, Januario E. Castro, MD, Gary J. Schiller, MD, Houston Holmes, MD, Mehrdad Abedi, MD, Armin Ghobadi, MD, Martha L. Arellano, MD, Adriana K. Malone, MD, John M. Pagel, MD PhD, Armen Mardiros, PhD, Tong Shen, MS, Remus Vezan, MD PhD, Rajul K. Jain, MD, Bijal D. Shah, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 897.
https://doi.org/10.1182/blood-2018-99-111531
Published: 2018
Journal Articles

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Don M. Benson, Jr., MD PhD, Houston Holmes, MD, Parameswaran Hari, MBBS, MD, Jessica Sachs, MD, Ben Exter, Ann Ranger, PhD, Tooba Cheema, PhD, Iga Sienczylo, BS, Megan M. O'Meara, MD, Django Sussman, PhD, Luke P. Akard, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1997.
https://doi.org/10.1182/blood-2018-99-111729
Published: 2018
Journal Articles

Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Bijal D. Shah, MD, Wendy Stock, MD, William G Wierda, MD PhD, Olalekan Oluwole, MBBS, MPH, Houston Holmes, MD FACP, Gary J. Schiller, MD FACP, Max S. Topp, MD, Marie José Kersten, MD PhD, Roch Houot, MD PhD, Nicolas Boissel, MD PhD, Michelle Mojadidi, MSc, Allen Xue, PhD, Armen Mardiros, PhD, Yizhou Jiang, PhD, Tong Shen, PhD, Jeff S. Aycock, Shanna Stout, Jeffrey S. Wiezorek, MD MS, Rajul Jain, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 888.
https://doi.org/10.1182/blood.V130.Suppl_1.888.888
Published: 2017
Journal Articles

Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-δ,γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab

Carla Casulo, MD, Juan-Manuel Sancho, Koen Van Eygen, MD, Sven de Vos, MD PhD, Santiago Mercadal, MD, Roderick J. Johnson, MD, Kamal Bouabdallah, MD, Houston Holmes, MD FACP, Jan Lemmens, MD, Emmanuel Gyan, MD, Michele Merli, MD, Ranjana H Advani, MD, Lori Steelman, MA, Joseph Pearlberg, MD PhD, Andre Goy, MD
Journal: Blood
Blood (2016) 128 (22): 2979.
https://doi.org/10.1182/blood.V128.22.2979.2979
Published: 2016
Journal Articles

Phase II Study of Clofarabine and Cytosine Arabinoside in Adult Patients with Relapsed AML and in Elderly Patients with Untreated AML Who Are at High Risk of Anthracycline Toxicity.

Edward Agura, MD, R. Brian Berryman, MD, Laura Brougher, RN, Barry Cooper, MD, Andrew De Leon, RPh, Joseph Fay, MD, Houston Holmes, MD, Christopher Maisel, MD, Arturo Molina, MD, Luis Pineiro, MD, Giovanna Saracino, MD, Mirjana Tadic-Ovcina, MD, Estil Vance, MD
Journal: Blood
Blood (2006) 108 (11): 1951.
https://doi.org/10.1182/blood.V108.11.1951.1951
Published: 2006